Alchemab has developed a highly differentiated platform which enables the identification of novel drug targets and therapeutics by analysis of patient antibody repertoires. The platform uses well-defined patient samples, deep B cell sequencing, and computational analysis to identify convergent protective antibody responses among individuals that are susceptible but resilient to specific diseases.

Alchemab is building a broad pipeline of protective therapeutics for hard-to-treat diseases, with an initial focus on neurodegenerative conditions and oncology. The highly specialized patient samples that power Alchemab’s platform are made available through valued partnerships and collaborations with patient representative groups, biobanks, industry partners, and academic institutions.

Alchemab Therapeutics Executive Leadership Team

• Jane Osbourn, Chief Executive Officer
• Olivia Cavlan, Chief Corporate Development and Strategy Officer
• Ralph Minter, Chief Scientific Officer
• Peter Catalano, Head of Finance
• Alex Hewitson, Chief Operating Officer
• Paul Varley, Chief Development Officer

Alchemab Therapeutics Board of Directors

• Kate Bingham, Chair
• Andrew Levin, Director
• Jane Osbourn
• John Hamer, Director
• Kevin Lee, Director

Alchemab Therapeutics Scientific Founders

• Rachel Bashford-Rogers
• Ben Larman
• Ruth McKernan
• Uri Laserson